Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.46 |
| ▸ | SYK | P43405 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 4/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.40 |
| ▸ | MERTK | Q12866 | 4/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640487 | 0.81 | BRAF (0.46) | EGFRERBB2IGF1RSYKBRAF | |
| SCHEMBL1644028 | 0.78 | AURKA (0.68) | EGFRERBB2IGF1RACVR1SYK | |
| SCHEMBL1641713 | 0.78 | SYK (0.49) | EGFRIGF1RSYKKCNH2AURKA | |
| SCHEMBL12726485 | 0.77 | ABL1 (0.53) | EGFRERBB2IGF1RACVR1SYK | |
| SCHEMBL13816255 | 0.77 | SYK (0.48) | EGFRIGF1RSYKKCNH2AURKA | |
| SCHEMBL1641782 | 0.76 | EGFR (0.46) | EGFRERBB2IGF1RSYKKDR | |
| SCHEMBL12726479 | 0.76 | AURKA (0.56) | EGFRERBB2IGF1RACVR1KCNH2 | |
| SCHEMBL1640332 | 0.75 | AURKA (0.42) | EGFRERBB2IGF1RACVR1SYK | |
| SCHEMBL1641024 | 0.74 | IGF1R (0.47) | EGFRIGF1RSYKKCNH2KDR | |
| SCHEMBL1640538 | 0.74 | KDR (0.45) | EGFRERBB2IGF1RACVR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| WO-2009076140-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | PDXK, MAP3K1, MAP4K2 | EGFR 478/4885ERBB2 69/4885IGF1R 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.